$5.37
5.09% yesterday
Nasdaq, Nov 28, 06:45 pm CET
ISIN
US74019P1084
Symbol
DTIL

Precision BioSciences, Inc. Stock price

$5.11
-2.07 28.83% 1M
+0.53 11.57% 6M
+1.30 34.12% YTD
-1.75 25.51% 1Y
-35.39 87.38% 3Y
-340.19 98.52% 5Y
-474.89 98.94% 10Y
-474.89 98.94% 20Y
Nasdaq, Closing price Wed, Nov 26 2025
+0.23 4.71%
ISIN
US74019P1084
Symbol
DTIL
Industry

Key metrics

Basic
Market capitalization
$67.7m
Enterprise Value
$45.2m
Net debt
positive
Cash
$44.9m
Shares outstanding
12.1m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
96.8 | 6.1
EV/Sales
64.6 | 4.1
EV/FCF
negative
P/B
4.1
Financial Health
Equity Ratio
41.4%
Return on Equity
12.7%
ROCE
-114.0%
ROIC
-
Debt/Equity
1.3
Financials (TTM | estimate)
Revenue
$700.0k | $11.0m
EBITDA
$-88.1m | $-67.6m
EBIT
$-89.5m | $-72.8m
Net Income
$-83.6m | $-71.3m
Free Cash Flow
$-73.7m
Growth (TTM | estimate)
Revenue
-99.1% | -84.0%
EBITDA
-582.1% | -188.5%
EBIT
-452.3% | -178.3%
Net Income
-1,069.8% | -1,095.0%
Free Cash Flow
-52.4%
Margin (TTM | estimate)
Gross
-
EBITDA
-12,625.6% | -613.9%
EBIT
-12,822.6%
Net
-11,977.4% | -647.6%
Free Cash Flow
-10,559.3%
More
EPS
$-7.1
FCF per Share
$-6.1
Short interest
2.3%
Employees
108
Rev per Employee
$640.0k
Show more

Is Precision BioSciences, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,070 stocks worldwide.

Precision BioSciences, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

9 Analysts have issued a Precision BioSciences, Inc. forecast:

8x Buy
89%
1x Hold
11%

Analyst Opinions

9 Analysts have issued a Precision BioSciences, Inc. forecast:

Buy
89%
Hold
11%

Financial data from Precision BioSciences, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '25
+/-
%
0.70 0.70
99% 99%
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 35 35
1% 1%
4,941%
- Research and Development Expense 54 54
1% 1%
7,749%
-88 -88
582% 582%
-12,590%
- Depreciation and Amortization 1.38 1.38
58% 58%
197%
EBIT (Operating Income) EBIT -90 -90
452% 452%
-12,786%
Net Profit -84 -84
1,070% 1,070%
-11,943%

In millions USD.

Don't miss a Thing! We will send you all news about Precision BioSciences, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Precision BioSciences, Inc. Stock News

Neutral
Business Wire
9 days ago
DURHAM, N.C.--(BUSINESS WIRE)--Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for high unmet need diseases, today announced that it will deliver an oral presentation at the Hep-DART 2025 meeting, to take place December 7–11, 2025, at the Hilton Hawaiian Village in Honolul...
Neutral
Seeking Alpha
17 days ago
Precision BioSciences, Inc. ( DTIL ) Discusses ARCUS Platform Progress and ELIMINATE-B Clinical Trial Update for Chronic Hepatitis B November 11, 2025 8:00 AM EST Company Participants Naresh Tanna - Chief of Staff to CEO & Head of Investor Relations Michael Amoroso - President, CEO & Director Mark Sulkowski Cassie Gorsuch - Chief Scientific Officer John Kelly - CFO & Principal Accounting Office...
Neutral
Business Wire
18 days ago
DURHAM, N.C.--(BUSINESS WIRE)--Precision BioSciences, Inc. (Nasdaq: DTIL) (“Precision”), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for high unmet need diseases, today announced that it has agreed to sell by way of an underwritten offering 10,815,000 shares of its common stock and accompanying warrants to purch...
More Precision BioSciences, Inc. News

Company Profile

Precision BioSciences, Inc. is a biotechnology company, which engages in the development of genome editing technologies. It operates through the Therapeutics and Food segments. The Therapeutics segment focuses on the development of products in the field of immuno-oncology and of novel products outside immuno-oncology to treat human diseases. The Food segment applies ARCUS, the company's propriety genome editing platform, to develop food and nutrition products through collaboration agreements with consumer-facing companies. The company was founded by Derek N. Jantz, Jeff Smith, and Matthew R. Kane in January 2006 and is headquartered in Durham, NC.

Head office United States
CEO Michael Amoroso
Employees 108
Founded 2006
Website precisionbiosciences.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today